Epidemiology of Pneumococcal Disease in a National Cohort of Older Adults

Infectious Diseases and Therapy

Volumn 3, Issue 1, 2014, Pages 19-33

  Morrill, Haley J ^a,b   Caffrey, Aisling R ^a,b   Noh, Eunsun ^a,b   LaPlante, Kerry L ^a,b,c  

^a PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

Epidemiology; Infectious disease; Pneumococcal disease; Streptococcus pneumonia; United States; Veteran

Indexed keywords

PNEUMOCOCCUS VACCINE;

AGED; ARTICLE; BACTEREMIA; BACTERIAL PNEUMONIA; CHRONIC LIVER DISEASE; DIABETES MELLITUS; FEMALE; HEART FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MORBIDITY; MORTALITY; NEOPLASM; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; STREPTOCOCCUS PNEUMONIAE; TOBACCO USE;

EID: 84977071128     PISSN: 21938229     EISSN: 21936382     Source Type: Journal    
DOI: 10.1007/s40121-014-0025-y     Document Type: Article

References (58)

1. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Surveillance reports: Streptococcus pneumoniae. 2002-2011. http://www. cdc. gov/abcs/reports-findings/surv-reports. html. Accessed Nov 2013.
2. File TM Jr. Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern. Am J Med. 2004;117(Suppl 3A): 39S-50S.
3. Hathaway LJ, Brugger SD, Morand B, Bangert M, Rotzetter JU, Hauser C, et al. Capsule type of Streptococcus pneumoniae determines growth phenotype. PLoS Pathog. 2012;8(3): e1002574.
4. Bridy-Pappas AE, Margolis MB, Center KJ, Isaacman DJ. Streptococcus pneumoniae: description of the pathogen, disease epidemiology, treatment, and prevention. Pharmacotherapy. 2005;25(9): 1193-212.
5. Austrian R. Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention. Rev Infect Dis. 1981;3(Suppl): S1-17.
6. Austrian R. The pneumococcus at the millennium: not down, not out. J Infect Dis. 1999;179(Suppl 2): S338-41.
7. Kyaw MH, Christie P, Clarke SC, Mooney JD, Ahmed S, Jones IG, et al. Invasive pneumococcal disease in Scotland, 1999-2001: use of record linkage to explore associations between patients and disease in relation to future vaccination policy. Clin Infect Dis. 2003;37(10): 1283-91.
8. Kyaw MH, Rose CE Jr, Fry AM, Singleton JA, Moore Z, Zell ER, et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis. 2005;192(3): 377-86.
9. Pastor P, Medley F, Murphy TV. Invasive pneumococcal disease in Dallas County, Texas: results from population-based surveillance in 1995. Clin Infect Dis. 1998;26(3): 590-5.
10. Redd SC, Rutherford GW 3rd, Sande MA, Lifson AR, Hadley WK, Facklam RR, et al. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J Infect Dis. 1990;162(5): 1012-7.
11. van Hoek AJ, Andrews N, Waight PA, Stowe J, Gates P, George R, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012;65(1): 17-24.
12. Siemieniuk RA, Gregson DB, Gill MJ. The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort study. BMC Infect Dis. 2011;11: 314.
13. Albrich WC, Baughman W, Schmotzer B, Farley MM. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44(12): 1569-76.
14. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294(16): 2043-51.
15. Shah SS, Ratner AJ. Trends in invasive pneumococcal disease-associated hospitalizations. Clin Infect Dis. 2006;42(1): e1-5.
16. Centers for Disease C, Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. Morb Mortal Wkly Rep. 2005;54(36): 893-7.
17. Talbot TR, Poehling KA, Hartert TV, Arbogast PG, Halasa NB, Mitchel E, et al. Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in tennessee after introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2004;39(5): 641-8.
18. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348(18): 1737-46.
19. Alshammari TM, Larrat EP, Morrill HJ, Caffrey AR, Quilliam BJ, Laplante KL. Risk of hepatotoxicity associated with fluoroquinolones: a national case-control safety study. Am J Health Syst Pharm. 2014;71(1): 37-43.
20. Caffrey AR, Morrill HJ, Puzniak LA, Laplante KL. Comparative effectiveness of linezolid and vancomycin among a National Veterans Affairs Cohort with methicillin-resistant Staphylococcus aureus Pneumonia. Pharmacotherapy. 2014. [Epub ahead of print].
21. Caffrey AR, LaPlante KL. Changing epidemiology of methicillin-resistant Staphylococcus aureus in the Veterans Affairs Healthcare System, 2002-2009. Infection. 2012;40(3): 291-7.
22. Caffrey AR, Quilliam BJ, LaPlante KL. Comparative effectiveness of linezolid and vancomycin among a national cohort of patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2010;54(10): 4394-400.
23. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11): 1130-9.
24. Agency for Healthcare Research and Quality. Clinical Classifications Software (CCS), Healthcare Cost and Utilization Project (HCUP). Rockville, MD: agency for Healthcare Research and Quality. 2009. http://www. hcup. us. ahrq. gov/toolssoftware/ccs/ccs. jsp. Accessed July 2012.
25. Pichon B, Ladhani SN, Slack MP, Segonds-Pichon A, Andrews NJ, Waight PA, et al. Changes in molecular epidemiology of streptococcus pneumoniae causing meningitis following introduction of pneumococcal conjugate vaccination in England and Wales. J Clin Microbiol. 2013;51(3): 820-7.
26. Centers for Disease C, Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep. 2012;61: 816-9.
27. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369(9568): 1179-86.
28. Grijalva CG, Poehling KA, Nuorti JP, Zhu Y, Martin SW, Edwards KM, et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics. 2006;118(3): 865-73.
29. Poehling KA, Szilagyi PG, Grijalva CG, Martin SW, LaFleur B, Mitchel E, et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics. 2007;119(4): 707-15.
30. Metlay JP, Lautenbach E, Li Y, Shults J, Edelstein PH. Exposure to children as a risk factor for bacteremic pneumococcal disease: changes in the post-conjugate vaccine era. Arch Intern Med. 2010;170(8): 725-31.
31. Davidson M, Parkinson AJ, Bulkow LR, Fitzgerald MA, Peters HV, Parks DJ. The epidemiology of invasive pneumococcal disease in Alaska, 1986-1990-ethnic differences and opportunities for prevention. J Infect Dis. 1994;170(2): 368-76.
32. Wroe PC, Finkelstein JA, Ray GT, Linder JA, Johnson KM, Rifas-Shiman S, et al. Aging population and future burden of pneumococcal pneumonia in the United States. J Infect Dis. 2012;205(10): 1589-92.
33. Villa VM, Harada ND, Washington D, Damron-Rodriguez J. The health and functional status of US veterans aged 65+: implications for VA health programs serving an elderly, diverse veteran population. Am J Med Qual. 2003;18(3): 108-16.
34. Shay K, Burris JF, State of the Art Planning C. Setting the stage for a new strategic plan for geriatrics and extended care in the Veterans Health Administration: summary of the 2008 VA State of the Art Conference, "The changing faces of geriatrics and extended care: meeting the needs of veterans in the next decade". J Am Geriatr Soc. 2008;56(12): 2330-9.
35. United States Department of Veterans Affairs, National Center for Veterans Analysis and Statistics. Profile of Veterans: 2009: United States Department of Veterans Affairs, National Center for Veterans Analysis and Statistics. 2011. http://www. va. gov/vetdata/docs/SpecialReports/Profile_of_Veterans_2009_FINAL. pdf. Accessed July 2012.
36. Jackson ML, Neuzil KM, Thompson WW, Shay DK, Yu O, Hanson CA, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis. 2004;39(11): 1642-50.
37. Musher DM, Alexandraki I, Graviss EA, Yanbeiy N, Eid A, Inderias LA, et al. Bacteremic and nonbacteremic pneumococcal pneumonia. A prospective study. Medicine. 2000;79(4): 210-21.
38. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2): S27-72.
39. Broome CV, Facklam RR. Epidemiology of clinically significant isolates of Streptococcus pneumoniae in the United States. Rev Infect Dis. 1981;3(2): 277-81.
40. Potgieter PD, Hammond JM. The intensive care management, mortality and prognostic indicators in severe community-acquired pneumococcal pneumonia. Intensive Care Med. 1996;22(12): 1301-6.
41. Tleyjeh IM, Tlaygeh HM, Hejal R, Montori VM, Baddour LM. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2006;42(6): 788-97.
42. Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med. 2004;170(4): 440-4.
43. Aspa J, Rajas O, Rodriguez de Castro F, Huertas MC, Borderias L, Cabello FJ, et al. Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J. 2006;27(5): 1010-9.
44. Kalin M, Ortqvist A, Almela M, Aufwerber E, Dwyer R, Henriques B, et al. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis. 2000;182(3): 840-7.
45. Sandvall B, Rueda AM, Musher DM. Long-term survival following pneumococcal pneumonia. Clin Infect Dis. 2013;56(8): 1145-6.
46. Hook EW 3rd, Horton CA, Schaberg DR. Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. JAMA. 1983;249(8): 1055-7.
47. Ortqvist A, Grepe A, Julander I, Kalin M. Bacteremic pneumococcal pneumonia in Sweden: clinical course and outcome and comparison with non-bacteremic pneumococcal and mycoplasmal pneumonias. Scand J Infect Dis. 1988;20(2): 163-71.
48. Alanee SR, McGee L, Jackson D, Chiou CC, Feldman C, Morris AJ, et al. Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin Infect Dis. 2007;45(1): 46-51.
49. Yu VL, Chiou CC, Feldman C, Ortqvist A, Rello J, Morris AJ, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis. 2003;37(2): 230-7.
50. Vardakas KZ, Matthaiou DK, Falagas ME. Adjunctive dexamethasone therapy for bacterial meningitis in adults: a meta-analysis of randomized controlled trials. Eur J Neurol. 2009;16(6): 662-73.
51. Jha AK, Wright SM, Perlin JB. Performance measures, vaccinations, and pneumonia rates among high-risk patients in Veterans Administration health care. Am J Public Health. 2007;97(12): 2167-72.
52. Greene CM, Kyaw MH, Ray SM, Schaffner W, Lynfield R, Barrett NL, et al. Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001-2003. Clin Infect Dis. 2006;43(2): 141-50.
53. Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA. 2001;285(13): 1729-35.
54. Centers for Disease C, Prevention. Noninfluenza vaccination coverage among adults-United States, 2011. Morb Mortal Wkly Rep. 2013;62(4): 66-72.
55. Petersen LA, Wright S, Normand SL, Daley J. Positive predictive value of the diagnosis of acute myocardial infarction in an administrative database. J Gen Intern Med. 1999;14(9): 555-8.
56. Kramer JR, Davila JA, Miller ED, Richardson P, Giordano TP, El-Serag HB. The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther. 2008;27(3): 274-82.
57. Schneeweiss S, Robicsek A, Scranton R, Zuckerman D, Solomon DH. Veteran's affairs hospital discharge databases coded serious bacterial infections accurately. J Clin Epidemiol. 2007;60(4): 397-409.
58. Abraham NS, Cohen DC, Rivers B, Richardson P. Validation of administrative data used for the diagnosis of upper gastrointestinal events following nonsteroidal anti-inflammatory drug prescription. Aliment Pharmacol Ther. 2006;24(2): 299-306.